JPMorgan Chase & Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by JPMorgan Chase & Co. on December 20, 2006, covering events reported as of December 19, 2006. The filing serves to incorporate specific exhibits by reference into the company's Registration Statement on Form S-3ASR (File No. 333-130051).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding exhibits and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing focuses solely on the submission of a legal opinion related to a specific debt instrument.
Guidance, Outlook, and Unusual Items
The filing references a Tax Opinion from Davis Polk & Wardwell concerning 9.75% Reverse Exchangeable Notes due December 27, 2007. These notes are linked to the common stock of Gilead Sciences, Inc. No management commentary, forward-looking guidance, or risk factors are detailed in the text of this specific 8-K.
Investor Verification Checklist
- Verify the terms of the 9.75% Reverse Exchangeable Notes due December 27, 2007, linked to Gilead Sciences, Inc.
- Review the full text of the Tax Opinion by Davis Polk & Wardwell (Exhibit 8.1) for tax implications.
- Consult the referenced Registration Statement on Form S-3ASR (333-130051) for broader context on the securities offering.